Skip to content

Trial · Observational

CompletedPhase not statedRegistry data

Coronary Flow Reserve Changes After Semaglutide Treatment

NCTNCT07190144 (opens ClinicalTrials.gov in a new tab)Other idIstanbulU-EBKaraayvaz-2
Open at ClinicalTrials.govAsk about this trial

This trial does not test a peptide that PepBank tracks.

  • Measures Semaglutide, does not give it. It appears in an outcome measure.

Overview

Status
Completed
Phase
Phase not stated
Enrollment
122 participants (actual)
Sponsor
Ekrem Bilal Karaayvaz · Other
Design
Not stated
Countries
1 country

Turkey (Türkiye)

Start
7 Jan 2025
Primary completion
1 Aug 2025
Completion
1 Aug 2025
First posted
24 Sept 2025
Last update posted
24 Sept 2025
Conditions
The Study Focused on the Vascular Effects of Semaglutide in Both Diabetic and Non-diabetic Patients · Obesity &Amp; Overweight

Timeline

1 trial · 1 completed

  • Completed
  • Ongoing
  • Not yet recruiting
  • Stopped
  • Estimated dates (est.)
  • Results posted
20252026
  1. Ph –

    Coronary Flow Reserve Changes After Semaglutide Treatment

    NCT07190144

    7 Jan 2025 to 1 Aug 2025

Registry summary

Text and fields below are the sponsor's entries at ClinicalTrials.gov, shown as posted.

The goal of this observational study is to learn about the effects of semaglutide to coronary artery flow in diabetic and non-diabetic patients. The main question it aims to answer is: Does semaglutide enhance coronary artery flow in diabetic and non-diabetic patients? Participants already planned taking semaglutide by an endocrine specialist as their treatment was assessed with CFR before and 3 months after.

Arms2

  • Other

    Non-diabetic patients

    Non-diabetic patients who have planned to given semaglutide by an endocrinology specialist, mostly to give weight, were performed CFR with echocardiography before and 3 months after the treatment.

  • Other

    Diabetic patients

    Diabetic patients, who were planned to start semaglutide by an endocrinology specialist and were otherwise has same demographic data as non-diabetic patients, were performed CFR with echocardiography before and 3 months after the treatment

Primary outcomes1

Outcomes the sponsor listed as primary.

  1. Number of patients who had acute coronary syndrome

    Time frame · From start of the study to 3 months after

    Registry description

    Semaglutide is known for its beneficial effects on coronary vasculature. If a patient had myocardial infarction, this patient can no longer participate in study because the CFR ultimately changes.

Secondary outcomes(1)

  1. Number of patients who can not lose weight

    Time frame · From start to 3 months

    Registry description

    Semaglutide is not only a diabetic drug but is also known for its weight loss properties. If the patient is unable to lose weight, additional information should be obtained as to why the drug is not working for this specific patient and should be removed from the study.

Posted results

Values are shown as posted at ClinicalTrials.gov, with their units. PepBank has not converted, pooled or compared them.

No results are posted for this trial.

Completed trials do not always post results.

Registry data comes from ClinicalTrials.gov. Study results come from studies, not from the registry. How PepBank works

Studies2

Studies that cite this trial.

Studies with results

2 studies on this page

Indexing hint: Randomized controlled trial · 2023

2 results

Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.

Lincoff et al. 2023The New England journal of medicinecited by 2,458

PMID 37952131DOI 10.1056/nejmoa2307563PUB-37952131

Rights unknown2 results
Source linkSee results (2)

Indexing hint: Randomized controlled trial · 2016

8 results

Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.

Marso et al. 2016The New England journal of medicinecited by 5,002

PMID 27633186DOI 10.1056/nejmoa1607141PUB-27633186

Rights unknown8 results
Source linkSee results (8)

Eligibility

Who could join, as posted.

Sex
All
Age
from 28 Years up to 65 Years
Healthy volunteers
Not accepted
Inclusion and exclusion criteria, as posted
Inclusion Criteria: * Patients who were planned to start semaglutide. Exclusion Criteria: * Ischemic heart disease * Previous stent implantation or coronary bypass * Heart failure * Cardiomyopathies * Inflammatory diseases * Autoimmune rheumatic disease * Chronic liver and renal insufficiency

PepBank is a research reference. Talk to a doctor before you use any peptide.